Parexel, one of the world’s largest clinical research organizations
(CROs) providing the full range of Phase I to IV clinical
development services, today announced the release of its 2023
Environmental, Social and Governance ("ESG") Report. The ESG Report
is part of Parexel’s annual commitment to disclose and communicate
the progress of its sustainability priorities, underscoring the
company’s core values of putting Patients First and delivering With
Heart™.
"Our ESG progress in 2023 reflects our ongoing commitment to
making a positive impact on the world around us by integrating
sustainable, ethical practices into and across our business and our
care for patients to transform the future of medicine,” said Peyton
Howell, Chief Executive Officer. “I’d like to thank our team for
their dedication to ensuring this progress continues. We recognize
that sustainability is a journey, not an endpoint, and as a team,
each of us at Parexel remains committed to using our resources to
not only meet but exceed our ESG goals in pursuit of creating a
healthier planet and improving the lives of the patients we
serve.”
Highlights of the company’s progress include:
Advancing Opportunities for Parexel’s
Workforce
Parexel’s diverse global workforce fuels creativity and
innovation to better address complex challenges and push the
boundaries. In 2023, women represented 70.2% of Parexel’s
workforce, including 45.6% of all employees at Vice President-level
and above.
Parexel fosters an environment where everyone feels empowered to
contribute to the company’s success, and the company’s Talent
Philosophy is designed to support colleagues globally in realizing
their full potential across all stages of their career. In 2023,
Parexel launched its Managers Matter initiative, designed to
engage, inform and inspire the company’s 2,300 Line Managers with
comprehensive support and resources to develop and lead their
teams.
In recognition of these and many other Diversity, Equity and
Inclusion (DEI) efforts, Parexel joined DisabilityIN as a corporate
partner and participated in their global disability inclusion index
pilot and the Human Rights Campaign’s 2023 Corporate Equality
Index. The company also won the Healthcare Businesswomen’s
Association 2023 ACE Award for its work advancing women in
leadership.
Actively Managing and Improving Sustainability
Performance
Parexel is consistently looking for ways to reduce its
environmental footprint while increasing operational excellence
across its business and has made progress toward its ambitious
environmental goals. In 2024, Parexel submitted science-based
emission reduction targets for validation with the Science Based
Target initiative (SBTi), setting a pathway to achieve net-zero
value chain greenhouse gas (GHG) emissions (Scopes 1, 2, and 3) by
2050.
The company continues to ensure it is reducing emissions by
enhancing energy efficiency in buildings and counterbalancing
emissions produced by our fleet of vehicles and our third-party
providers. Parexel made this a priority focus in 2023 and for the
second consecutive year it achieved a 100% renewable energy goal to
counterbalance all Scope 2 emissions.
Parexel also participated in the EcoVadis assessment process for
the ninth consecutive year, increasing its score to 60 points from
58 points in 2022 and maintaining its Silver rating and ranking in
the top quartile of companies for the second straight year. The
accomplishments of its environmental program place Parexel in the
top 7% of organizations in the scientific research and development
category and its sustainable procurement program ranks us in the
top 1% in the field.
Enhancing the Engagement and Experience of Patients
Worldwide
Through its collaborations with patient advocacy and social
organizations around the world, Parexel continues to provide
education, drive awareness and reduce barriers to participation
through the design of inclusive clinical trials with its partners
for all study phases.
In 2023, Parexel engaged with more than 75 patient advocacy
groups around the world to support the needs of patient communities
and elevate awareness of clinical trials. The company continuously
refines its approach to support patients holistically, especially
in populations that have been historically underrepresented as the
industry adapts to a changing regulatory environment.
Operating with Integrity
Parexel leads with its core values – Patients First, Quality,
Respect and Empowerment and Accountability – and conducts
businesses with honesty, integrity and respect. An important
element of the company’s commitment to these standards is its
compliance program.
In 2023, Parexel established principles for responsible
Artificial Intelligence (AI) and has created a robust governance
structure with the creation of its AI Steering Committee to ensure
safety, efficiency and regulatory compliance in the use of this
technology.
The company has also introduced the Parexel Precision Pathway,
reinforcing its commitment to product quality and safety. This
end-to-end operational approach is designed to prioritize the
timely delivery of clean data while enhancing efficiency, quality
and predictability.
To view Parexel’s 2023 ESG Report, please visit:
https://newsroom.parexel.com/esg
About Parexel
Parexel is among the world’s largest clinical research
organizations (CROs), providing the full range of Phase I to IV
clinical development services to help life-saving treatments reach
patients faster. Leveraging the breadth of our clinical, regulatory
and therapeutic expertise, our team of more than 21,000 global
professionals works in partnership with biopharmaceutical leaders,
emerging innovators and sites to design and deliver clinical trials
with patients in mind, increasing access and participation to make
clinical research a care option for anyone, anywhere. Our depth of
industry knowledge and strong track record gained over the past 40
years is moving the industry forward and advancing clinical
research in healthcare’s most complex areas, while our innovation
ecosystem offers quality solutions to make every phase of the
clinical trial process more efficient. With the people, insight and
focus on operational excellence, we work With HeartTM every day to
treat patients with dignity and continuously learn from their
experiences, so every trial makes a difference. This approach
continues to earn us recognition industrywide, with Parexel being
named “Best Contract Research Organization” in November 2023 by an
independent panel for Citeline, “Top CRO to Work With” by
investigative sites worldwide in the 2023 WCG CenterWatch Global
Site Relationship Benchmark Survey and recipient of the 2023
Society for Clinical Research Sites (SCRS) Eagle Award for
advancing the clinical research profession through strong site
partnerships. For more information, visit parexel.com and follow us
on LinkedIn, X, Facebook and Instagram.
MEDIA
Lori Preuit Dorer+1 513 496 8121Lori.Dorer@parexel.com
Addison Stallings+1 984 833
6362Addison.Stallings@parexel.com